TRIJARDY XR: payments to doctors
Payments that named TRIJARDY XR as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $413K
- Providers
- 11,152
- Transactions
- 25,124
- Average per transaction
- $16
The per-transaction average — $16 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 11,152 providers the average total is $37, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Boehringer Ingelheim | $336,035 | 81.4% |
| Lilly USA, LLC | $76,220 | 18.5% |
| Eli Lilly Export S.A. Puerto Rico Branch | $772 | 0.2% |